Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera
NCT04644211Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in essential thrombocythemia (ET) and polycythemia vera (PV) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Percentage of patients who achieve >50% reduction from baseline to Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score at 12 weeks. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
essential thrombocythemia (ET)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT04644211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644211.